<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103139</url>
  </required_header>
  <id_info>
    <org_study_id>HS-16-00520</org_study_id>
    <nct_id>NCT03103139</nct_id>
  </id_info>
  <brief_title>Endoscopic Stenting Across the Papilla Versus the Leak Site to Treat Bile Leak</brief_title>
  <official_title>Randomized Controlled Trial Of Endoscopic Stenting Across the Papilla Versus the Leak Site to Treat Bile Leak</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Biliary duct injury are a relatively frequent complication of hepatobiliary surgery,
           most comonly laparoscopic cholecystecomy.

        2. Prior to the development of more sophisticated endoscopic interventions, repeat surgery
           was often necessary for the management of biliary leaks.

        3. Advances in technique and technology in gastroenterology endoscopy have largely replaced
           surgery as the first line intervention for biliary leak.

        4. Most practices utilize endoscopic plastic biliary stent placement alone and are
           efficacious and equivalent to the biliary stent placement with endoscopic biliary
           sphincterotomy.

        5. An area of variation is in whether biliary stent should cross the papilla ( with a
           shorter stent) versus the site of the bile leak (with a longer stent).

        6. Our objective is to assess whether placing a biliary stent across the leak versus across
           the papilla alone improves the treatment of biliary leaks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.0 BACKGROUND 1.1) Biliary duct injuries are a relatively frequent complications of
      hepatobiliary surgery, most commonly laparoscopic cholecystectomy1. Such injuries can
      manifest clinically in a number of ways including biliary leakage, biliary stricture
      formation, or associated infectious complications. Biliary leakage is the most common of
      these postoperative complications and is estimated to be clinically significant in 0.8 to
      1.1% of such surgeries.

      Prior to the development of more sophisticated endoscopic interventions, repeat surgery was
      often necessary for management of biliary leaks. However, advances in technique and
      technology in gastrointestinal endoscopy have largely replaced surgery as a first line
      intervention for biliary leaks. The generally accepted goal in the endoscopic management of
      biliary leaks is to equalize the pressure between the biliary system and the duodenum, so as
      to allow bile to flow into the lower pressure small bowel and thereby affording the leak time
      to close.

      How to best achieve this goal has been a topic of considerable interest. Randomized studies
      have shown that endoscopic plastic biliary stent placement alone is highly efficacious and
      equivalent to biliary stent placement with endoscopic biliary sphincterotomy. Thin (7
      French[Fr]) and wide (10 French) diameter stents seem to have similar efficacy with regards
      to leak resolution. Beyond these well-validated techniques, there are other variations in
      clinical practice that are not supported by high-levels of evidence.

      1.2) One area of variation is in whether the biliary stent should cross the papilla (with a
      shorter stent) versus the site of the leak (with a longer stent).

      2.0 OBJECTIVES AND PURPOSE

      To assess whether placing a biliary stent across the leak versus across the papilla alone
      improves the treatment of biliary leaks.

      3.0 STUDY DESIGN:

      The study will be a prospective randomized controlled trial. All patients undergoing
      Endoscopic Retrograde Cholangiopancreatography (ERCP) for the treatment of bile leaks will be
      eligible for inclusion (see section and initial collection form). During the ERCP if
      cholangiogram demonstrates a leak, the patient will be randomized to either A) papillary
      stenting strategy or B) crossing the leak site strategy. Please see the diagram below to
      complement the written description of the study design.

      A) In the papillary stenting strategy, regardless of where the leak is identified, a stent is
      placed into the duodenal papilla and into the most distal (proximal to duodenum) portion of
      the bile duct. The goal of this strategy is to use the stent to keep the papilla open,
      thereby decreasing the pressure gradient and allowing for bile to flow preferentially into
      the duodenum away from the leaking area. All stents in this strategy will be 7 Fr in diameter
      and 5 cm long.

      B) In the crossing the leak strategy (left), once the area of bile leakage is identified in
      the biliary tree, a stent will be placed endoscopically across the leaking area. This
      theoretically allows the underlying injured bile duct tissue to heal. The same diameter stent
      (7Fr) as the papillary stenting strategy will be used but the length will vary in order to
      bridge the leaking region (5-15cm).

      The decision whether or not to perform sphincterotomy will be entirely determined by the
      attending endoscopist and not part of the study. The 7Fr stents we are using may be easily
      placed whether or not a sphincterotomy is performed. It will be recorded whether or not a
      sphincterotomy was performed. All procedures evaluated in this study are done as part of
      standard clinical care.

      Following the initial ERCP intervention, the patients will receive routine post-procedural
      care. They will have serial monitoring.

      CRITERIA FOR EVALUATION AND ENDPOINT DEFINITIONS

      The primary outcome will be a successful resolution of bile leak with the ERCP strategy. This
      will require will require 2 criterion:

      A. No further leakage of bile on the follow up ERCP at 5 weeks. Resolution is confirmed by
      the demonstration of no leaking of contrast from the prior leakage site on cholangiography.

      B. No ERCP or other procedure has to be done between the initial ERCP and the 5 week ERCP to
      treat the bile leak.

      The proportion of patients in each randomized arm with the resolution of bile leak at 5 weeks
      will be compared.

      There will be several secondary outcomes:

      A. Time from ERCP to removal of surgical drain (days) B. Time from ERCP to complete cessation
      of output from drain (days) C. Presence of other significant findings on the 5th week
      cholangiogram. These include bile duct stone or biliary stricture.

      D. Requirement of surgery to treat the bile leak. E. Endoscopic complications of the 1st and
      2nd ERCP including pancreatitis, bleeding perforation, cholangitis, and stent occlusion
      within 5 weeks of initial or 2nd ERCP.

      STATISTICAL CONSIDERATONS:

      Patients will be randomized in a 1:1 fashion to either the papillary stenting strategy group
      or crossing the leak stenting strategy group.

      Dichotomous outcomes including primary outcome (successful resolution of the bile leakage)
      will be compared using a Fischer's exact or chi squared test. Continuous baseline
      charactersistics or outcomes will be compared using a Wilcoxan rank sum test or T test
      depending on distribution. If imbalances occur, logistic regression models will be developed
      to control for these imbalances as covariates in the primary outcome model. Secondary
      outcomes involving time to clinical improvement in the arms will be compared using Cox
      Regression analysis, allowing for the inclusion of covariates depending on degree of balance
      of baseline characteristics. Analyses will be performed using SPSS v.23 and SAS v9; two-sided
      p = 0.05 will be used for primary and secondary outcomes.

      Based on a retrospective query of the 32 consecutive previous cases of bile leaks managed at
      the Los Angeles County hospital using stents which did or did not bridge the leak we used
      G*Power to estimate that a total sample size of 88 will be adequate (2 sided alpha of 0.05
      and beta of 0.2) to detect an 20% difference (80 vs 99%) in successful resolution of bile
      leak in the two groups. Based on data from the past 1 year at Los Angles County hospital it
      was estimated that there would be a 5% 5-week attrition thus the sample size was determined
      to be 92 patients.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with resolution of bile leak by cholangiography</measure>
    <time_frame>within 5 weeks</time_frame>
    <description>The primary outcome is the proportion of patients with resolution of bile leak determined by cholangiography at 5 weeks among the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to from ERCP to remove surgical drain</measure>
    <time_frame>within 5 weeks</time_frame>
    <description>The time from the ERCP to removal of surgical drain will be compared in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who required surgery</measure>
    <time_frame>within 10 weeks</time_frame>
    <description>The proportion of patients who require surgery the manage the bile leaks in the two groups were compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Bile Leak</condition>
  <arm_group>
    <arm_group_label>Transpapillary Stents</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stent placement across the Papilla (with a short plastic stent) for biliary leak</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stent across bile leak</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stent placement across the bile leak (with a longer stent) for biliary leak</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transpapillary Stent</intervention_name>
    <description>ERCP with placement of short stent</description>
    <arm_group_label>Transpapillary Stents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stent across bile leak</intervention_name>
    <description>ERCP with long stent</description>
    <arm_group_label>Stent across bile leak</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing ERCP for the treatment of suspected acute bile leaks will be
             eligible for inclusion (bile leaks felt to be complications of surgical intervention).
             A patient is suspected to have an acute bile leak if the patient is referred within
             two weeks following the original surgery.. Legally authorized representatives may
             serve as surrogates to consent for inclusion in this study.

        Bile leaks are suspected based on the following:

        A) Persistent, significant drainage of bilious fluid from post-surgical drains following
        hepatobiliary surgery or cholecystectomy,.

        B) Compatible symptoms plus imaging findings on abdominal ultrasonography, computed
        tomography, HIDA scanning, or MRCP of an abnormal intra-abdominal fluid collection in the
        setting of recent hepatobiliary surgery.

        Exclusion Criteria:

          -  Patients with bile duct transection (in which the duct has been totally severed into 2
             parts) will be excluded as these are known to not be amenable to endoscopic therapy.
             Further, suspected bile leaks of non-surgical etiology will be excluded from the study
             (malignancy, trauma, spontaneous perforation, and other rarer causes). Bile leaks
             suspected two weeks post surgery will also not be included. Additionally patients who
             are pregnant, imprisoned, under age 18, unable to give informed consent, or have
             undergone prior biliary diversion surgery will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Buxbaum, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Buanes T, Waage A, Mj√•land O, Solheim K. Bile leak after cholecystectomy significance and treatment: results from the National Norwegian Cholecystectomy Registry. Int Surg. 1996 Jul-Sep;81(3):276-9.</citation>
    <PMID>9028989</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossi RL, Schirmer WJ, Braasch JW, Sanders LB, Munson JL. Laparoscopic bile duct injuries. Risk factors, recognition, and repair. Arch Surg. 1992 May;127(5):596-601; discussion 601-2.</citation>
    <PMID>1533509</PMID>
  </results_reference>
  <results_reference>
    <citation>Barkun AN, Rezieg M, Mehta SN, Pavone E, Landry S, Barkun JS, Fried GM, Bret P, Cohen A. Postcholecystectomy biliary leaks in the laparoscopic era: risk factors, presentation, and management. McGill Gallstone Treatment Group. Gastrointest Endosc. 1997 Mar;45(3):277-82.</citation>
    <PMID>9087834</PMID>
  </results_reference>
  <results_reference>
    <citation>Davids PH, Ringers J, Rauws EA, de Wit LT, Huibregtse K, van der Heyde MN, Tytgat GN. Bile duct injury after laparoscopic cholecystectomy: the value of endoscopic retrograde cholangiopancreatography. Gut. 1993 Sep;34(9):1250-4.</citation>
    <PMID>8406163</PMID>
  </results_reference>
  <results_reference>
    <citation>Fasoulas K, Zavos C, Chatzimavroudis G, Trakateli C, Vasiliadis T, Ioannidis A, Kountouras J, Katsinelos P. Eleven-year experience on the endoscopic treatment of post-cholecystectomy bile leaks. Ann Gastroenterol. 2011;24(3):200-205.</citation>
    <PMID>24713781</PMID>
  </results_reference>
  <results_reference>
    <citation>Bjorkman DJ, Carr-Locke DL, Lichtenstein DR, Ferrari AP, Slivka A, Van Dam J, Brooks DC. Postsurgical bile leaks: endoscopic obliteration of the transpapillary pressure gradient is enough. Am J Gastroenterol. 1995 Dec;90(12):2128-33.</citation>
    <PMID>8540501</PMID>
  </results_reference>
  <results_reference>
    <citation>Mavrogiannis C, Liatsos C, Papanikolaou IS, Karagiannis S, Galanis P, Romanos A. Biliary stenting alone versus biliary stenting plus sphincterotomy for the treatment of post-laparoscopic cholecystectomy biliary leaks: a prospective randomized study. Eur J Gastroenterol Hepatol. 2006 Apr;18(4):405-9.</citation>
    <PMID>16538112</PMID>
  </results_reference>
  <results_reference>
    <citation>Katsinelos P, Kountouras J, Paroutoglou G, Chatzimavroudis G, Germanidis G, Zavos C, Pilpilidis I, Paikos D, Papaziogas B. A comparative study of 10-Fr vs. 7-Fr straight plastic stents in the treatment of postcholecystectomy bile leak. Surg Endosc. 2008 Jan;22(1):101-6. Epub 2007 May 22.</citation>
    <PMID>17516115</PMID>
  </results_reference>
  <results_reference>
    <citation>Nawaz H, Papachristou GI. Endoscopic treatment for post-cholecystectomy bile leaks: update and recent advances. Ann Gastroenterol. 2011;24(3):161-163.</citation>
    <PMID>24713786</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>James Buxbaum</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

